NGS in the Diagnosis of Neonatal Diseases

Status Not yet recruiting

Clinical Trial Summary

To investigate the application of NGS in neonatal disease screening and diagnosis, two studies was conducted (the other ID is: shercru-20220003). This study is to evaluate the application of NGS in the diagnosis of neonatal disease.

Clinical Trial Description

As health care has improved, genetic diseases have become the leading cause of infant death in hospitalized neonatal. However, due to extensive clinical and genetic heterogeneity, differential diagnosis of all known genetic disorders is often a challenging and lengthy process. Current clinical potential genetic diagnosis of ill baby often undergo repeated consulting, several times repeated invasive testing and/or metabolic examination, and efficiency is not high, which lead to children's and family's heavy mental pressure and economic burden. Targeted sequencing, also known as next Generation sequence (NGS), has the advantages of fast sequencing, wide sequencing range, high sensitivity, high accuracy and low cost compared with traditional sequencing technology (Sanger sequencing). NGS has been widely used in tumor diseases, prenatal screening, drugs and the diagnosis of various genetic diseases. In prenatal screening, targeted sequencing is gradually used to detect free fetal DNA in pregnant women's peripheral blood, with an accuracy of 95%, which is much better than traditional amniocentesis karyotype analysis and improves the detection rate of secondary birth defects. Compared with traditional methods, NGS can provide diagnosis and classification, rich genetic disease gene spectrum, accurate direction for treatment, as well as the predict the risk of the next generation of children of the same disease. Therefore, targeted sequencing technology has great advantages for the diagnosis of children and prevention of newborn birth defect diseases. To evaluate the efficacy of NGS in the screening and diagnosis of neonatal disease, the investigator lauched the "Budding Action". This study is to evaluate the application of NGS in the diagnosis of neonatal disease. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05476055
Study type	Observational
Source	Shanghai Children's Hospital
Contact	Lin Zou
Phone	18623121280
Email	zoulin@shchildren.com.cn
Status	Not yet recruiting
Phase
Start date	August 2022
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02785926` - Impact of Antenatal Exposure to Pesticides on Neurophysiological Functions (Sleep, Respiration) of Preterm Neonates
Completed	`NCT01946971` - Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)	Phase 1/Phase 2
Completed	`NCT01530360` - Cerebral Oxygenation to Guide Medical Interventions in Extremely Preterm Infants	Phase 1
Completed	`NCT00681018` - Feeding Study in Premature Infants	N/A
Completed	`NCT00217191` - Ibuprofen and Renal Function in Premature Infants	Phase 4
Completed	`NCT01077271` - Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA	N/A
Completed	`NCT00282113` - Effects of Probiotic and Prebiotic Combinations on Premature Infants	N/A
Active, not recruiting	`NCT02943746` - Targeted Protein Fortification in Extremely Low Birth Weight Preterm Infants	N/A
Completed	`NCT01994954` - A Randomized Trial of Outpatient Oxygen Weaning Strategies in Premature Infants	N/A
Completed	`NCT00389909` - Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants	Phase 4
Completed	`NCT00747591` - Urine Concentration of S100B in Extremely Premature Infants	N/A
Recruiting	`NCT04555590` - Implementation of an Evidence Based Parentally Administered Intervention for Preterm Infants	N/A
Completed	`NCT06352047` - The Effects of Positioning After Extubation of Preterm Infants on the Respiratory Functions	N/A
Completed	`NCT03217045` - Nutrition Protocol and Premature Infants' Growth
Recruiting	`NCT03552952` - Development of Preterm Infant Gut Microbiome
Recruiting	`NCT06332521` - Infant Crying, a Bioacoustic Prognostic Signal for Neurodevelopment
Completed	`NCT04659083` - How NAVA Works in Preterm Infants With Irregular Respiratory Efforts
Completed	`NCT05807191` - The Effect of Using Clinical Guidelines on Kangaroo Care on Newborn and Maternal Outcomes	N/A
Completed	`NCT03914690` - Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage	Phase 2
Completed	`NCT01140243` - Infant Formula Supplemented With a Special Fat Formulation for Premature Infants Following Discharge From Hospital	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.